(VIANEWS) – The NASDAQ opens in less than one hour and FibroGen‘s pre-market value is already 4.5% up.

FibroGen’s last close was $0.95, 96.31% below its 52-week high of $25.69.

The last session, NASDAQ finished with FibroGen (FGEN) sliding 14.65% to $0.95. NASDAQ jumped 1.14% to $13,917.89, after two consecutive sessions in a row of gains, on what was an all-around bullish trend exchanging session.

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.49.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1015.79%.

Sales Growth

FibroGen’s sales growth is 134.7% for the ongoing quarter and 14.6% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FibroGen’s EBITDA is -0.54.

Yearly Top and Bottom Value

FibroGen’s stock is valued at $0.95 at 09:25 EST, way under its 52-week high of $25.69 and above its 52-week low of $0.90.

More news about FibroGen (FGEN).